Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol phase 3 trial in moderate to severe chronic plaque psoriasis
NL-OMON47061Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Nov 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in psoriasis (4 arms), sponsored by UCB. Primary endpoint: PASI75 response at Week 12. Started Nov 2015; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON47061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47061.